{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:44:31Z","timestamp":1791999871354,"version":"4.4.0"},"reference-count":198,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy Bucharest, Romania","id":[{"id":"https:\/\/ror.org\/04fm87419","id-type":"ROR","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/04fm87419","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Cardiovascular complications increasingly challenge survivors of urological cancers, given the cardiotoxicity of therapies such as androgen deprivation, vascular endothelial growth factor receptor inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, and chemotherapy. This narrative review addresses the complex crosstalk between urological cancer treatment and cardiovascular disease. It summarizes cardiovascular toxicities linked to major antineoplastic agents, explores underlying mechanisms including metabolic and immune-mediated effects, and proposes strategies for surveillance, diagnosis, and management. Highlighting the need for multidisciplinary collaboration, it outlines future directions for research to optimize cardiovascular outcomes in this high-risk population. The increasing complexity of cardiovascular care in patients with urological malignancies highlights the need for closer collaboration between cardiologists, urologists, and oncologists, with uro-cardio-oncology emerging as an important multidisciplinary field.<\/jats:p>","DOI":"10.3390\/diagnostics16152452","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:16:27Z","timestamp":1785766587000},"page":"2452","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular Complications Associated with Uro-Oncology Treatments\u2014A Primer for the Clinician"],"prefix":"10.3390","volume":"16","author":[{"given":"Diana-Ligia","family":"Pena","sequence":"first","affiliation":[{"name":"Department of Cardiology, \u201cProf. Dr. Theodor Burghele\u201d Clinical Hospital, 061344 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana-Mihaela","family":"Ilie\u0219iu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"\u201cProf. Dr. Theodor Burghele\u201d Clinical Hospital, 061344 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5478-5766","authenticated-orcid":false,"given":"Justin","family":"Aurelian","sequence":"additional","affiliation":[{"name":"\u201cProf. Dr. Theodor Burghele\u201d Clinical Hospital, 061344 Bucharest, Romania"},{"name":"Department of Urology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-0130","authenticated-orcid":false,"given":"Mihai","family":"Grigore","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"\u201cProf. Dr. Theodor Burghele\u201d Clinical Hospital, 061344 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea-Simona","family":"Hodorogea","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"\u201cProf. Dr. Theodor Burghele\u201d Clinical Hospital, 061344 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Coriu-Georgescu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"\u201cProf. Dr. Theodor Burghele\u201d Clinical Hospital, 061344 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-3054","authenticated-orcid":false,"given":"Elisabeta","family":"Badil\u0103","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-5328","authenticated-orcid":false,"given":"Viorel","family":"Jinga","sequence":"additional","affiliation":[{"name":"\u201cProf. Dr. Theodor Burghele\u201d Clinical Hospital, 061344 Bucharest, Romania"},{"name":"Department of Urology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Balahura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"\u201cProf. Dr. Theodor Burghele\u201d Clinical Hospital, 061344 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wilk, M., Wa\u015bko-Grabowska, A., and Szmit, S. (2020). Cardiovascular Complications of Prostate Cancer Treatment. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.555475"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaccao.2024.09.012","article-title":"Cardiovascular Risk in Prostate Cancer","volume":"6","author":"Leong","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kakkat, S., Pramanik, P., Singh, S., Singh, A.P., Sarkar, C., and Chakroborty, D. (2023). Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24086984"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A Population-Based Study of Cardiovascular Disease Mortality Risk in US Cancer Patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular Risk Factors and Morbidity in Long-Term Survivors of Testicular Cancer: A 20-Year Follow-Up Study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular Complications of Cancer Therapy","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1002\/cai2.108","article-title":"Cardiovascular Disease Burden in Patients with Urological Cancers: The New Discipline of Uro-cardio-oncology","volume":"3","author":"Zheng","year":"2024","journal-title":"Cancer Innov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.31925\/farmacia.2021.6.5","article-title":"CARDIOTOXICITY OF ANTICANCER THERAPIES: FOCUS ON THE ROLE OF THE CARDIO-ONCOLOGICAL TEAM. A PRACTICAL REVIEW","volume":"69","author":"Gheorghe","year":"2021","journal-title":"Farmacia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune Checkpoint Inhibitor\u2013Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/CIR.0000000000000986","article-title":"Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association","volume":"144","author":"Fradley","year":"2021","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"41","author":"Brugada","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11886-021-01561-9","article-title":"Cardiovascular Toxicity of Androgen Deprivation Therapy","volume":"23","author":"Boland","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"188383","DOI":"10.1016\/j.bbcan.2020.188383","article-title":"Cardiovascular Risks and Toxicity\u2014The Achilles Heel of Androgen Deprivation Therapy in Prostate Cancer Patients","volume":"1874","author":"Muniyan","year":"2020","journal-title":"Biochim. ET Biophys. Acta Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2016.71.4204","article-title":"Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/JU.0000000000002340","article-title":"Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients with Prostate Cancer","volume":"207","author":"Kan","year":"2022","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2017.06.036","article-title":"Gonadotropin-Releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-Ecologic, Nationwide, Population-Based Study","volume":"72","author":"Thomsen","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2022.0334","article-title":"Cardiovascular Complications of Treatment for Prostate Cancer","volume":"83","author":"Ferreira","year":"2022","journal-title":"Br. J. Hosp. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S520","DOI":"10.1016\/j.annonc.2020.08.890","article-title":"631P Darolutamide (D), Enzalutamide (E) and Apalutamide (A), the Risk of Adverse Events (AEs) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC): Number Needed to Harm (NNH)","volume":"31","author":"George","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"10","author":"Taktak","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00345-025-05841-9","article-title":"Association between Major Cardiovascular Events and Abiraterone Acetate Compared to Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the EVADE Study","volume":"43","author":"Bahl","year":"2025","journal-title":"World J. Urol."},{"key":"ref_28","first-page":"97","article-title":"Clinical Use of Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer","volume":"6","author":"Fong","year":"2014","journal-title":"Res. Rep. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00432-006-0133-5","article-title":"Antiandrogen Treatments in Locally Advanced Prostate Cancer: Are They All the Same?","volume":"132","author":"Gillatt","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Clarke, N.W., Armstrong, A.J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., De Menezes, J., Girotto, G., and Arslan, C. (2022). Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid., 1.","DOI":"10.1056\/EVIDoa2200043"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cpt.2024.04.004","article-title":"Cardiotoxicity in Platinum-Based Chemotherapy: Mechanisms, Manifestations, and Management","volume":"3","author":"Rachma","year":"2025","journal-title":"Cancer Pathog. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Herrad\u00f3n, E., Gonz\u00e1lez, C., Uranga, J.A., Abalo, R., Mart\u00edn, M.I., and L\u00f3pez-Miranda, V. (2017). Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00196"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41416-020-01049-3","article-title":"Vascular Aging in Long-Term Survivors of Testicular Cancer More than 20 Years after Treatment with Cisplatin-Based Chemotherapy","volume":"123","author":"Stelwagen","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1200\/JCO.2016.70.3108","article-title":"Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy","volume":"35","author":"Fung","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.6004\/jnccn.2025.7120","article-title":"Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting","volume":"24","author":"Kerns","year":"2026","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer","volume":"381","author":"Sternberg","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Shao, C., Wan, Q., Guo, J., and Chen, Z. (2025). The Efficacy and Safety of Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis Based on Randomized Controlled Trials. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1586650"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1758835918780140","DOI":"10.1177\/1758835918780140","article-title":"5-Fluorouracil and Cardiotoxicity: A Review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","article-title":"Randomized Phase III Trial of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-Invasive Bladder Cancer. Analysis of the GETUG\/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_42","first-page":"oyaf203","article-title":"Incidence and Risk of Hypertension and Proteinuria in Cancer Patients Treated with Lenvatinib: A Systematic Review and Meta-Analysis","volume":"30","author":"Shibutani","year":"2025","journal-title":"Oncology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"pkaa076","DOI":"10.1093\/jncics\/pkaa076","article-title":"Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews","volume":"4","author":"Luu","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Yuan, T., Li, F., Hou, Y., and Guo, H. (2023). Adverse Events in Patients with Advanced Urothelial Carcinoma Treated with Erdafitinib: A Retrospective Pharmacovigilance Study. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1266890"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Torres-Jim\u00e9nez, J., Albarr\u00e1n-Fern\u00e1ndez, V., Pozas, J., Rom\u00e1n-Gil, M.S., Esteban-Villarrubia, J., Carrato, A., Rosero, A., Grande, E., Alonso-Gordoa, T., and Molina-Cerrillo, J. (2021). Novel Tyrosine Kinase Targets in Urothelial Carcinoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020747"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2640342","DOI":"10.1155\/2018\/2640342","article-title":"mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?","volume":"2018","author":"Kezic","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9692528","DOI":"10.1155\/2019\/9692528","article-title":"mTOR Signaling in Cardiometabolic Disease, Cancer, and Aging 2018","volume":"2019","author":"Das","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Su\u00e1rez, C., Vieito, M., Valdivia, A., Gonz\u00e1lez, M., and Carles, J. (2023). Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors. Med. Sci., 11.","DOI":"10.3390\/medsci11030046"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"101154","DOI":"10.1016\/j.esmoop.2023.101154","article-title":"Major Adverse Cardiac Events and Cardiovascular Toxicity with PARP Inhibitors-Based Therapy for Solid Tumors: A Systematic Review and Safety Meta-Analysis","volume":"8","author":"Palazzo","year":"2023","journal-title":"ESMO Open"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Long, P., Li, S., Pan, L., Wang, Y., Chen, W., and Wang, X. (2024). Cardiovascular Adverse Events Associated with Antibody-Drug Conjugates (ADCs): A Pharmacovigilance Study Based on the FAERS Database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1378010"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune Checkpoint Inhibitor\u2013Induced Cardiotoxicity: A Systematic Review and Meta-Analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mauriello, A., Correra, A., Maratea, A.C., Cetoretta, V., Benfari, G., Ilardi, F., Cocchia, R., Lisi, M., Malagoli, A., and Mandoli, G.E. (2026). Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020814"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11912-024-01634-2","article-title":"Cardiotoxic Effects Following CAR-T Cell Therapy: A Literature Review","volume":"27","author":"Joseph","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kjellstadli, C., Forster, R.B., Myklebust, T.\u00c5., Bj\u00f8rge, T., B\u00f8naa, K.H., Helle, S.I., and Kv\u00e5le, R. (2023). Cardiovascular Outcomes after Curative Prostate Cancer Treatment: A Population-Based Cohort Study. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1121872"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.21037\/tau-21-835","article-title":"Effects of Radical Cystectomy, Radiotherapy, and Chemotherapy on the Risk of Long-Term Heart-Specific Death in Bladder Cancer Patients","volume":"10","author":"Yang","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/UPJ.0000000000000878","article-title":"Adverse Cardiovascular Outcomes of Individuals Treated With Androgen Deprivation Therapy","volume":"12","author":"Li","year":"2025","journal-title":"Urol. Pract."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Fradin, J., Kim, F.J., Lu-Yao, G.L., Storozynsky, E., and Kelly, W.K. (2023). Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer. Cancers, 15.","DOI":"10.3390\/cancers15082316"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s11912-023-01424-2","article-title":"Cardiovascular Impact of Androgen Deprivation Therapy: From Basic Biology to Clinical Practice","volume":"25","author":"Kim","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/iju.13473","article-title":"Metabolic Changes in Patients with Prostate Cancer during Androgen Deprivation Therapy","volume":"25","author":"Mitsuzuka","year":"2018","journal-title":"Int. J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1464-410X.2008.07933.x","article-title":"Metabolic and Cardiovascular Effects of Androgen Deprivation Therapy","volume":"102","author":"Hakimian","year":"2008","journal-title":"BJU Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"23119","DOI":"10.1038\/s41598-024-73197-y","article-title":"Opposing Impact of Hypertension\/Diabetes Following Hormone Therapy Initiation and Preexisting Statins on Castration Resistant Progression of Nonmetastatic Prostate Cancer: A Multicenter Study","volume":"14","author":"Hayashi","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/pros.24244","article-title":"Endothelial Dysfunction after Androgen Deprivation Therapy and the Possible Underlying Mechanisms","volume":"82","author":"Teoh","year":"2022","journal-title":"Prostate"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e030447","DOI":"10.1161\/JAHA.123.030447","article-title":"Cancer Therapy\u2013Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy","volume":"12","author":"Chen","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/ATVBAHA.125.319867","article-title":"Vascular Toxicities of Cancer Therapies: 2025 Update","volume":"46","author":"Donisan","year":"2026","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3233\/CH-242128","article-title":"Is Fluid Retention a Cardiovascular Risk Factor?","volume":"88","author":"Blankfield","year":"2024","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Pena, D.-L., Ilie\u0219iu, A.-M., Aurelian, J., Grigore, M., Hodorogea, A.-S., Ciobanu, A., Weiss, E., Badil\u0103, E., and Balahura, A.-M. (2025). Assessment of Decongestion Status Before Discharge in Acute Decompensated Heart Failure: A Review of Clinical, Biochemical, and Imaging Tools and Their Impact on Management Decisions. Medicina, 61.","DOI":"10.3390\/medicina61050816"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"A378","DOI":"10.1016\/S0735-1097(18)30919-7","article-title":"Androgen deprivation therapy for prostate cancer and incident atrial fibrillation","volume":"71","author":"Ali","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Chen, D.-Y., Chen, C.-C., Tsai, M.-L., Chang, C.-Y., Hsieh, M.-J., Chen, T.-H., Su, P.-J., Chu, P.-H., Hsieh, I.-C., and Pang, S.-T. (2025). Predicting Cardiovascular Risk in Patients with Prostate Cancer Receiving Abiraterone or Enzalutamide by Using Machine Learning. Cancers, 17.","DOI":"10.3390\/cancers17152414"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Lazzerini, P.E., Bertolozzi, I., Acampa, M., Cantara, S., Castagna, M.G., Pieragnoli, L., D\u2019Errico, A., Rossi, M., Bisogno, S., and El-Sherif, N. (2020). Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00684"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e16131","DOI":"10.1200\/jco.2015.33.15_suppl.e16131","article-title":"Androgen Deprivation Therapy Use and the Risk of Venous Thromboembolism","volume":"33","author":"Yin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1002\/cncr.26623","article-title":"Androgen Deprivation and Thromboembolic Events in Men with Prostate Cancer","volume":"118","author":"Ehdaie","year":"2012","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5534\/wjmh.200109","article-title":"Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer","volume":"39","author":"Corona","year":"2021","journal-title":"World J. Mens. Health"},{"key":"ref_77","first-page":"508","article-title":"Androgen Deprivation Therapy and Cardiovascular Risk in Prostate Cancer","volume":"74","author":"Fiori","year":"2022","journal-title":"Minerva Urol. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/ATVBAHA.119.313046","article-title":"Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses","volume":"40","author":"Hu","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jaccao.2023.07.005","article-title":"Cardiovascular Toxicity During Advanced Prostate Cancer Treatment: Minding the Heart","volume":"5","author":"Dorff","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jaccao.2023.05.011","article-title":"Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review","volume":"5","author":"Nelson","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.euo.2024.09.004","article-title":"Comparative Cardiovascular Safety of Gonadotropin-Releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-Analysis of Real-World Evidence Studies","volume":"8","author":"Patel","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JU.0000000000003721","article-title":"Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone\u2013Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist","volume":"211","author":"Crawford","year":"2024","journal-title":"J. Urol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Sciarra, A., Busetto, G.M., Salciccia, S., Del Giudice, F., Maggi, M., Crocetto, F., Ferro, M., De Berardinis, E., Scarpa, R.M., and Porpiglia, F. (2021). Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.695170"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1200\/JCO.2020.38.15_suppl.5602","article-title":"HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist, versus Leuprolide Acetate for Advanced Prostate Cancer","volume":"38","author":"Shore","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1007\/s12325-023-02634-7","article-title":"Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer","volume":"40","author":"Shore","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11864-021-00846-z","article-title":"Cardiovascular Toxicities of Androgen Deprivation Therapy","volume":"22","author":"Challa","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s12094-024-03772-2","article-title":"A Systematic Review and Meta-Analysis of Cardiovascular Disease Risk with Degarelix and GnRH Agonists in Prostate Cancer","volume":"27","author":"Sano","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Liu, W., Liu, Z., Song, L., Zhu, H., Luo, Y., Zhang, J., Su, S., and Wang, D. (2025). Comparing the Risk of Cardiovascular Disease between Degarelix and Gonadotropin-Releasing Hormone Agonists:A Systematic Review and Meta-Analysis. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1523794"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e71487","DOI":"10.1002\/cam4.71487","article-title":"Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis","volume":"14","author":"Wang","year":"2025","journal-title":"Cancer Med."},{"key":"ref_90","unstructured":"(2026, July 11). Advanced Prostate Cancer: AUA\/SUO Guideline (2026)\u2014American Urological Association. Available online: https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/advanced-prostate-cancer."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Li, G., Zhang, X., Ma, Z., Ma, C., and An, Z. (2026). Interstitial Lung Disease Associated with Antiandrogen Agents: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System. Int. Urol. Nephrol.","DOI":"10.1007\/s11255-026-05205-1"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/106002809703100112","article-title":"Nilutamide: An Antiandrogen for the Treatment of Prostate Cancer","volume":"31","author":"Dole","year":"1997","journal-title":"Ann. Pharmacother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0090-4295(97)00279-3","article-title":"Clinical Benefits of Bicalutamide Compared with Flutamide in Combined Androgen Blockade for Patients with Advanced Prostatic Carcinoma: Final Report of a Double-Blind, Randomized, Multicenter Trial","volume":"50","author":"Schellhammer","year":"1997","journal-title":"Urology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41391-024-00886-0","article-title":"Cardiovascular Events among Men with Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-Analysis, and Network Meta-Analysis","volume":"28","author":"Matsukawa","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102066","DOI":"10.1016\/j.clgc.2024.102066","article-title":"Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"22","author":"Zhou","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-018-3632-6","article-title":"An Open-Label, Multicenter, Phase Ib Study Investigating the Effect of Apalutamide on Ventricular Repolarization in Men with Castration-Resistant Prostate Cancer","volume":"82","author":"Belderbos","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pros.24096","article-title":"Risk of Major Adverse Cardiovascular Events among Second-line Hormonal Therapy for Metastatic Castration-resistant Prostate Cancer: A Real-world Evidence Study","volume":"81","author":"Liu","year":"2021","journal-title":"Prostate"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"102148","DOI":"10.1016\/j.jgo.2024.102148","article-title":"Real-World Effectiveness and Cardiovascular Safety of Abiraterone versus Enzalutamide amongst Older Patients Diagnosed with Metastatic Castration-Resistant Prostate Cancer","volume":"16","author":"Gaber","year":"2025","journal-title":"J. Geriatr. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Hou\u00e9d\u00e9, N., Beuzeboc, P., Gourgou, S., Tosi, D., Moise, L., Gravis, G., Delva, R., Fl\u00e9chon, A., Latorzeff, I., and Ferrero, J.-M. (2015). Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: Long Term Outcome of the Temporary Authorization for Use Programme in France. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1257-2"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone Acetate plus Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-Sensitive Prostate Cancer (LATITUDE): Final Overall Survival Analysis of a Randomised, Double-Blind, Phase 3 Trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(26)00066-5","article-title":"On-Treatment Serum Prostate-Specific Antigen and Overall Survival in Prostate Cancer (STAMPEDE Platform Protocol): A Post-Hoc Analysis of Data from Five Phase 3 Trials","volume":"27","author":"Kayani","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clgc.2021.08.009","article-title":"Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data","volume":"20","author":"Hu","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e592","DOI":"10.1016\/j.clgc.2019.03.001","article-title":"Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-Resistant Prostate Cancer: Post-Marketing Experience","volume":"17","author":"Tsao","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Shaver, A.L., Nikita, N., Sharma, S., Keith, S.W., Zarrabi, K.K., Kelly, W.K., and Lu-Yao, G. (2025). The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials. Cancers, 17.","DOI":"10.3390\/cancers17172747"},{"key":"ref_107","first-page":"1132","article-title":"Cardiotoxicity of Chemotherapy and Targeted Agents","volume":"11","author":"Mudd","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"795602","DOI":"10.1155\/2015\/795602","article-title":"Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress","volume":"2015","author":"Angsutararux","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_109","first-page":"8","article-title":"Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management","volume":"1","author":"Shakir","year":"2009","journal-title":"J. Clin. Med. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15420\/ecr.2015.10.01.19","article-title":"Chemotherapy-Related Cardiomyopathy","volume":"10","author":"Piper","year":"2015","journal-title":"Eur. Cardiol. Rev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1023\/A:1008231521553","article-title":"Cardiac Arrhythmias after Cisplatin Infusion: Three Case Reports and a Review of the Literature","volume":"8","author":"Tassinari","year":"1997","journal-title":"Ann. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4172\/2157-7420.1000236","article-title":"Cisplatin-Related Atrial Fibrillation during PEB Chemotherapy for Testicular Seminoma: A Case Report","volume":"7","author":"Pastorino","year":"2016","journal-title":"J. Health Med. Inform."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10495-008-0214-9","article-title":"Pravastatin Attenuates Carboplatin-Induced Cardiotoxicity via Inhibition of Oxidative Stress Associated Apoptosis","volume":"13","author":"Cheng","year":"2008","journal-title":"Apoptosis"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Liu, J., Guan, W., Sun, Y., Wang, Y., Li, G., Zhang, S., and Shi, B. (2023). Early Detection of the Impact of Combined Taxane and Carboplatin Treatment on Autonomic Nerves in Patients with Cervical Cancer: Measurement of Heart Rate Variability. Front. Physiol., 14.","DOI":"10.3389\/fphys.2023.1126057"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Chen, X., Wang, H., Zhang, Z., Xu, Y., An, X., Ai, X., and Li, L. (2022). Case Report: Oxaliplatin-Induced Third-Degree Atrioventricular Block: First Discovery of an Important Side-Effect. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.900406"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s11255-024-04303-2","article-title":"Platinum-Based Chemotherapies-Induced Nephrotoxicity: Mechanisms, Potential Treatments, and Management","volume":"57","author":"Shahrahmani","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2024.06.006","article-title":"Cardiovascular Considerations After Cancer Therapy","volume":"7","author":"Blaes","year":"2025","journal-title":"JACC CardioOncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10741-025-10531-0","article-title":"Cancer Therapy-Induced Cardiotoxicity: Mechanisms and Mitigations","volume":"30","author":"Shil","year":"2025","journal-title":"Heart Fail. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","article-title":"Cardiac Disturbances during the Administration of Taxol","volume":"9","author":"Rowinsky","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_120","first-page":"23","article-title":"Doxorubicin and Paclitaxel, a Highly Active Combination in the Treatment of Metastatic Breast Cancer","volume":"23","author":"Dombernowsky","year":"1996","journal-title":"Semin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40959-025-00363-0","article-title":"Arrhythmias, Conduction Disorders and Sudden Cardiac Death in Cancer Patients and Survivors: Expert Opinion of the Working Groups on Cardio-Oncology and on Electrophysiology of the Hellenic Cardiac Society","volume":"11","author":"Keramida","year":"2025","journal-title":"Cardio Oncol."},{"key":"ref_122","first-page":"e43598","article-title":"A Case of Docetaxel-Induced Left Ventricular Outflow Tract Obstruction","volume":"15","author":"Mase","year":"2023","journal-title":"Cureus"},{"key":"ref_123","unstructured":"Vinereanu, D. (2025, September 24). Diagnosis and Prediction of Subclinical Cardiac Dysfunction Induced by Therapy with Taxanes in Patients with Breast Cancer, Available online: http:\/\/clinicaltrials.gov\/study\/NCT01641562."},{"key":"ref_124","first-page":"A16313","article-title":"Abstract 16313: Taxanes-Induced Cardiotoxicity in Patients With Breast Cancer: Diagnosis and Prediction. An Echo and Genetic Study","volume":"130","author":"Florescu","year":"2014","journal-title":"Circulation"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000471759","article-title":"A Prospective Study to Evaluate the Effect of Paclitaxel on Cardiac Ejection Fraction","volume":"12","author":"Osman","year":"2017","journal-title":"Breast Care"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12574-023-00618-8","article-title":"The Diagnostic Value of Global Longitudinal Strain Combined with Cardiac Biomarkers on Early Detection of Anthracycline-Related Cardiac Dysfunction","volume":"21","author":"Allam","year":"2023","journal-title":"J. Echocardiogr."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"580515","DOI":"10.2147\/BCTT.S580515","article-title":"Clinical Value of Cardiac Troponin I in Assessing Anthracycline-Induced Cardiotoxicity in Postoperative Breast Cancer Patients","volume":"18","author":"Li","year":"2026","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e0305","DOI":"10.15275\/rusomj.2020.0305","article-title":"Pathophysiological Mechanisms of Cardiotoxicity in Chemotherapeutic Agents","volume":"9","author":"Chaulin","year":"2020","journal-title":"Russ. Open Med. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152506775268785","article-title":"Cardiotoxicity of 5-Fluorouracil","volume":"4","author":"Alter","year":"2006","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines","volume":"21","author":"Shiga","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1445-5994.2009.02144.x","article-title":"Cardiotoxicity with 5-fluorouracil and Capecitabine: More than Just Vasospastic Angina","volume":"40","author":"Stewart","year":"2010","journal-title":"Intern. Med. J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ucl.2015.04.009","article-title":"Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors","volume":"42","author":"In","year":"2015","journal-title":"Urol. Clin. N. Am."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Grudzi\u0144ska, M., Czajkowski, M., Dolny, M., Matuszewski, M., Wierzbicki, P.M., Rybarczyk, A., and Hakenberg, O.W. (2025). Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens. Cancers, 18.","DOI":"10.3390\/cancers18010046"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jjco\/hyx071","article-title":"Cardiovascular Toxic Effects of Targeted Cancer Therapy","volume":"47","author":"Tajiri","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine Kinase Inhibitor-Induced Hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Wang, Y., Cui, C., Ren, X., Dong, X., and Cui, W. (2022). Cardiovascular Toxicity Associated with Angiogenesis Inhibitors: A Comprehensive Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System Database from 2014 to 2021. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.988013"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5152\/tud.2011.020","article-title":"Tyrosine Kinase Inhibitors for the Treatment of Metastatic Renal Cell Carcinoma: What Urologists Should Know?","volume":"37","author":"Kotb","year":"2011","journal-title":"Turk. J. Urol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse Effects of Tyrosine Kinase Inhibitors in Cancer Therapy: Pathophysiology, Mechanisms and Clinical Management","volume":"8","author":"Sharma","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/heartjnl-2024-325535","article-title":"Vascular Endothelial Growth Factor Inhibitor-Induced Cardiotoxicity: Prospective Multimodality Assessment Incorporating Cardiovascular Magnetic Resonance Imaging","volume":"111","author":"Dobbin","year":"2025","journal-title":"Heart"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, Everolimus, and the Combination in Patients with Metastatic Renal Cell Carcinoma: A Randomised, Phase 2, Open-Label, Multicentre Trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-Inducible Factor 2 Alpha (HIF2\u03b1) Inhibitors: Targeting Genetically Driven Tumor Hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocr. Rev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"17588359251317846","DOI":"10.1177\/17588359251317846","article-title":"Belzutifan for the Treatment of Renal Cell Carcinoma","volume":"17","author":"Wu","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2024.12.008","article-title":"Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Safety Meta-Analysis","volume":"72","author":"Maiorano","year":"2025","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Tian, X., Chen, L., Gai, D., He, S., Jiang, X., and Zhang, N. (2022). Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.851246"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Zhang, M., Zuo, Y., Chen, S., Li, Y., Xing, Y., Yang, L., Wang, H., and Guo, R. (2024). Antibody\u2013Drug Conjugates in Urothelial Carcinoma: Scientometric Analysis and Clinical Trials Analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1323366"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3233\/BLC-230070","article-title":"Efficacy of Antibody Drug Conjugates Alone and in Combination with Other Agents in Metastatic Urothelial Carcinoma: A Scoping Review","volume":"10","author":"Grant","year":"2024","journal-title":"Bladder Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody\u2013Drug Conjugates in Cancer Therapy: Current Landscape, Challenges, and Future Directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.annemergmed.2024.10.015","article-title":"Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know","volume":"85","author":"Markides","year":"2025","journal-title":"Ann. Emerg. Med."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Nguyen, T.D., Bordeau, B.M., and Balthasar, J.P. (2023). Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers, 15.","DOI":"10.3390\/cancers15030713"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Du, H., Wang, J., and Wang, Z. (2025). Cardiovascular Adverse Effects of Immunotherapy in Cancer: Insights and Implications. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1601808"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Liu, S., Gao, W., Ning, Y., Zou, X., Zhang, W., Zeng, L., and Liu, J. (2022). Cardiovascular Toxicity With PD-1\/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.908173"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/bab.2081","article-title":"Cardiotoxicity of Immune Checkpoint Inhibitors: An Updated Review","volume":"69","author":"Behravesh","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity Associated with CTLA4 and PD1 Blocking Immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular Toxicities of Immune Checkpoint Inhibitors","volume":"74","author":"Ball","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1186\/s12967-025-06768-w","article-title":"Cardiotoxicity in Cancer Immunotherapy: A Systematic Review and Global Meta-Analysis","volume":"23","author":"Zhou","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Wang, F., Wei, Q., and Wu, X. (2022). Cardiac Arrhythmias Associated with Immune Checkpoint Inhibitors: A Comprehensive Disproportionality Analysis of the FDA Adverse Event Reporting System. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.986357"},{"key":"ref_158","first-page":"54","article-title":"Immune Checkpoint Inhibitor\u2013Related Myocarditis: Recognition, Surveillance, and Management","volume":"26","author":"Kuhnly","year":"2022","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Stefanou, E., Tsitsinakis, G., Karageorgou, D., and Kole, C. (2025). Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology. Cancers, 17.","DOI":"10.3390\/cancers17172838"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Trontzas, I.P., Vathiotis, I.A., Kyriakoulis, K.G., Sofianidi, A., Spyropoulou, Z., Charpidou, A., Kotteas, E.A., Syrigos, K.N., and ImmunoTTS Collaborative Group (2023). Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases. Cancers, 15.","DOI":"10.3390\/cancers15092637"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","article-title":"2025 ESC Guidelines for the Management of Myocarditis and Pericarditis","volume":"46","author":"Collini","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Li, D., Yun, H., Liu, W., Chai, K., Tong, J., Zeng, T., Gao, Z., and Xie, Y. (2022). CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.915171"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","article-title":"Cardiovascular Events in Patients Treated with Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Lymphoma","volume":"107","author":"Steiner","year":"2022","journal-title":"Haematologica"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"15330338221132927","DOI":"10.1177\/15330338221132927","article-title":"Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions","volume":"21","author":"Dalal","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40959-024-00252-y","article-title":"Cardiac Adverse Events after Chimeric Antigen Receptor (CAR) T Cell Therapies: An Updated Systematic Review and Meta-Analysis","volume":"10","author":"Maleki","year":"2024","journal-title":"Cardio Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e2437222","DOI":"10.1001\/jamanetworkopen.2024.37222","article-title":"Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy for Advanced Hematologic Malignant Neoplasms: A Meta-Analysis","volume":"7","author":"Koeckerling","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Liu, J.-H., Liu, K.-Y., Zhao, X., Zhou, X., and Jiang, Y. (2025). Cardiovascular Toxicities Associated with Chimeric Antigen Receptor T-Cell Therapy. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1578157"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/ajkd.2001.26095","article-title":"Presentation and Revascularization Outcomes in Patients with Radiation-Induced Renal Artery Stenosis","volume":"38","author":"Fakhouri","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular Manifestations From Therapeutic Radiation","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00345-024-04852-2","article-title":"Cardiovascular Disease Risk Assessment and Multidisciplinary Care in Prostate Cancer Treatment with ADT: Recommendations from the APMA PCCV Expert Network","volume":"42","author":"Merseburger","year":"2024","journal-title":"World J. Urol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.35285","article-title":"A Practical Guide for Assessing and Managing Cardiovascular Risk during Androgen-deprivation Therapy in Patients with Prostate Cancer","volume":"130","author":"Solanki","year":"2024","journal-title":"Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0632","article-title":"Risk Assessment Prior to Cardiotoxic Anticancer Therapies in 7 Steps","volume":"86","author":"Tong","year":"2025","journal-title":"Br. J. Hosp. Med."},{"key":"ref_179","unstructured":"L\u00f3pez-Fernandez, T., and Dent, S.F. (2025, September 29). Strategies for Risk Stratification and Cardiovascular Toxicity Prevention in Patients with Cancer. Available online: https:\/\/www.escardio.org\/communities\/councils\/cardiology-practice\/education\/cardiopractice\/strategies-for-risk-stratification-and-cardiovascular-toxicity-prevention-in-pat\/."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41440-024-02015-9","article-title":"The Interplay between Cancer and Cardiovascular Disease","volume":"48","author":"Kuwabara","year":"2025","journal-title":"Hypertens. Res."},{"key":"ref_181","first-page":"10","article-title":"Efficacy and Safety of Cardioprotective Drugs in Chemotherapy-Induced Cardiotoxicity: An Updated Systematic Review & Network Meta-Analysis","volume":"9","author":"Mir","year":"2023","journal-title":"Cardiooncology"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Kourek, C., Touloupaki, M., Rempakos, A., Loritis, K., Tsougkos, E., Paraskevaidis, I., and Briasoulis, A. (2022). Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9080259"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Brown, S.-A. (2019). Preventive Cardio-Oncology: The Time Has Come. Front. Cardiovasc. Med., 6.","DOI":"10.3389\/fcvm.2019.00187"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/eurjpc\/zwaf026","article-title":"Impact of Sodium\u2013Glucose Cotransporter-2 Inhibitors on Heart Failure Outcomes in Cancer Patients and Survivors: A Systematic Review and Meta-Analysis","volume":"33","author":"Bhalraam","year":"2025","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Grigore, M., Nicolae, C., Grigore, A.-M., Balahura, A.-M., P\u0103un, N., Uscoiu, G., Verde, I., and Ilie\u0219iu, A.-M. (2025). Contemporary Perspectives on Congestion in Heart Failure: Bridging Classic Signs with Evolving Diagnostic and Therapeutic Strategies. Diagnostics, 15.","DOI":"10.3390\/diagnostics15091083"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eururo.2024.08.031","article-title":"Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-Analysis with Bayesian Modeling of Treatment Histories","volume":"87","author":"Aziz","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Grigore, A.-M., Grigore, M., Balahura, A.-M., Uscoiu, G., Verde, I., Nicolae, C., B\u0103dil\u0103, E., and Ilie\u0219iu, A.-M. (2025). The Role of the Estimated Plasma Volume Variation in Assessing Decongestion in Patients with Acute Decompensated Heart Failure. Biomedicines, 13.","DOI":"10.3390\/biomedicines13010088"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Advanced Bladder Cancer (ABC) (2005). Meta-analysis Collaboration Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Eur. Urol., 48, 202\u2013205; discussion 205\u2013206.","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and Cisplatin versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study","volume":"18","author":"Hansen","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of Patients With Metastatic Urothelial Cancer \u201cUnfit\u201d for Cisplatin-Based Chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1093\/oncolo\/oyad297","article-title":"Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review","volume":"29","author":"Sikking","year":"2024","journal-title":"Oncologist"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines","volume":"87","author":"Bruins","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_194","unstructured":"(2025, September 29). 184-Prevention and Management of Cisplatin Induced Nephrotoxicity|eviQ. Available online: https:\/\/www.eviq.org.au\/clinical-resources\/side-effect-and-toxicity-management\/prophylaxis-and-treatment\/184-prevention-and-management-of-cisplatin-induced."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1159\/000506992","article-title":"Efficacy of a Newly Modified Short Hydration Method for Gemcitabine and Cisplatin Combination Chemotherapy in Patients with Urothelial Carcinoma","volume":"98","author":"Naiki","year":"2020","journal-title":"Oncology"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Li, S., He, X., Ruan, L., Ye, T., Wen, Y., Song, Z., Hu, S., Chen, Y., Peng, B., and Li, S. (2021). Protective Effect of Mannitol on Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.804685"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11864-014-0320-6","article-title":"Corticosteroids in the Management of Prostate Cancer: A Critical Review","volume":"16","author":"Ndibe","year":"2015","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"103826","DOI":"10.1016\/j.critrevonc.2022.103826","article-title":"Corticosteroids in Oncology: Use, Overuse, Indications, Contraindications. An Italian Association of Medical Oncology (AIOM)\/Italian Association of Medical Diabetologists (AMD)\/Italian Society of Endocrinology (SIE)\/Italian Society of Pharmacology (SIF) Multidisciplinary Consensus Position Paper","volume":"180","author":"Faggiano","year":"2022","journal-title":"Crit. Rev. Oncol.\/Hematol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/15\/2452\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:46:35Z","timestamp":1791996395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/15\/2452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":198,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["diagnostics16152452"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16152452","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}